Skip to content

Assessing effectiveness of PRP and tranexamic acid + vitamne C mesotherapy in the treatment of periorbital dark circle

Comparision of the effectiveness of platelet-rich plasma (PRP) and tranexamic acid + vitamne C mesotherapy in the treatment of periorbital hyperpigmentation (POH)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200623047891N2
Enrollment
20
Registered
2022-08-21
Start date
2021-11-22
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periorbital hyperpigmentation. Other melanin hyperpigmentation

Interventions

Intervention 1: Intervention group: Intra dermal injection of 0.5cc tranexamic acid and 0.5cc vitamin C into the infraorbital region in 3 session with 3-week intervals.(at the beginning of the study,

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnosis of non-structural POH by dermatologist in Afzalipour hospital dermatology clinic Filling the written letter of satisfaction to participate in the project Minimum age of 18 when filling the letter of satisfaction Male or non-pregnant, non-breast feeding female gender

Exclusion criteria

Exclusion criteria: Smoking Previous or current bleeding disorders Using anti coagulant medications Presence of any active lesion in the treatment area

Design outcomes

Primary

MeasureTime frame
Severity of periorbital hyperpigmentation. Timepoint: At the begining of the study (before intervention) and 1 and 3 months after intervention. Method of measurement: Using Patient and Physician Global Assessment score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Iranmanesh

Kerman University of Medical Sciences

behzad_ariiana@yahoo.com+98 34 3132 8328

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026